Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Novel epitope begets a novel pathway in type 1 diabetes progression
Jeffrey A. Frelinger
Jeffrey A. Frelinger
Published September 18, 2008
Citation Information: J Clin Invest. 2008;118(10):3268-3271. https://doi.org/10.1172/JCI37125.
View: Text | PDF
Commentary

Novel epitope begets a novel pathway in type 1 diabetes progression

  • Text
  • PDF
Abstract

While CD8+ T cells are critical to diabetogenesis in NOD mice, evidence of their involvement in human type 1 diabetes (T1D) has been circumstantial. The existence of CD8+ T cells specific for β cell peptides has been demonstrated, but functional data regarding the role of these cells in T1D have been lacking. In this issue of the JCI, Skowera et al. describe an unusual self-peptide epitope derived from the leader sequence of preproinsulin (PPI) and show that 50% of HLA-A2+ patients with new-onset T1D possessed circulating CD8+ T cells specific for this epitope, suggesting that PPI plays a critical role in the development of T1D (see the related article beginning on page 3390). They also report that β cells upregulate PPI expression in the presence of high glucose levels, rendering these cells more susceptible to lysis and potentially accelerating disease. This suggests that interventions aimed at decreasing the PPI-specific CD8+ T cell response early after T1D diagnosis may be efficacious in ameliorating the disease process.

Authors

Jeffrey A. Frelinger

×

Figure 1

Model for the development of T1D, elucidating the role of PPI-specific CD8+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
Model for the development of T1D, elucidating the role of PPI-specific C...
This image shows a schematic of an islet before the onset of T1D, with relatively low levels of PPI-derived peptides (as determined in the study in this issue of the JCI by Skowera et al.; ref. 7) expressed on β cells and few or no T cells. Following migration of a dendritic cell to the draining lymph node, both CD4+ and CD8+ T cells are activated and migrate to the islets. There they encounter PPI-expressing β cells and kill them, resulting in lowered levels of insulin and hyperglycemia, as suggested by Skowera et al. (7). This results in increased PPI production and PPI presentation on both the β cells and resident dendritic cells. This can result in increased sensitivity to killing of β cells by CD8+ T cells (7), as well as in local proliferation of the effectors stimulated by resident dendritic cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts